Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs
- Tuesday, January 5, 2021, 2:26
- Business
- Add a comment
TOKYO and CAMBRIDGE, England, Jan. 5, 2021 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it is to regain the worldwide rights to its muscarinic agonist programs. The program was licensed to Allergan in April 2016, and Allergan was acquired by AbbVie in May…
About the Author
adminasapcorp has written 41546 stories on this site.